Rhythm Pharmaceuticals (RYTM) EBIAT: 2016-2025
Historic EBIAT for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -$52.9 million.
- Rhythm Pharmaceuticals' EBIAT fell 21.23% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 25.72%. This contributed to the annual value of -$260.6 million for FY2024, which is 41.11% down from last year.
- According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' EBIAT is -$52.9 million, which was down 13.45% from -$46.6 million recorded in Q2 2025.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIAT peaked at $65.8 million during Q1 2021, and registered a low of -$141.4 million during Q1 2024.
- In the last 3 years, Rhythm Pharmaceuticals' EBIAT had a median value of -$46.6 million in 2025 and averaged -$54.0 million.
- Per our database at Business Quant, Rhythm Pharmaceuticals' EBIAT skyrocketed by 292.47% in 2021 and then plummeted by 180.24% in 2022.
- Over the past 5 years, Rhythm Pharmaceuticals' EBIAT (Quarterly) stood at -$42.9 million in 2021, then grew by 0.87% to -$42.5 million in 2022, then rose by 2.02% to -$41.6 million in 2023, then declined by 3.98% to -$43.3 million in 2024, then decreased by 21.23% to -$52.9 million in 2025.
- Its EBIAT stands at -$52.9 million for Q3 2025, versus -$46.6 million for Q2 2025 and -$49.5 million for Q1 2025.